1
|
Mohanty S, Desai VM, Jain R, Agrawal M, Dubey SK, Singhvi G. Unveiling the potential of photodynamic therapy with nanocarriers as a compelling therapeutic approach for skin cancer treatment: current explorations and insights. RSC Adv 2024; 14:21915-21937. [PMID: 38989245 PMCID: PMC11234503 DOI: 10.1039/d4ra02564d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2024] [Accepted: 07/02/2024] [Indexed: 07/12/2024] Open
Abstract
Skin carcinoma is one of the most prevalent types of carcinomas. Due to high incidence of side effects in conventional therapies (radiotherapy and chemotherapy), photodynamic therapy (PDT) has gained huge attention as an alternate treatment strategy. PDT involves the administration of photosensitizers (PS) to carcinoma cells which produce reactive oxygen species (ROS) on irradiation by specific wavelengths of light that result in cancer cells' death via apoptosis, autophagy, or necrosis. Topical delivery of PS to the skin cancer cells at the required concentration is a challenge due to the compounds' innate physicochemical characteristics. Nanocarriers have been observed to improve skin permeability and enhance the therapeutic efficiency of PDT. Polymeric nanoparticles (NPs), metallic NPs, and lipid nanocarriers have been reported to carry PS successfully with minimal side effects and high effectiveness in both melanoma and non-melanoma skin cancers. Advanced carriers such as quantum dots, microneedles, and cubosomes have also been addressed with reported studies to show their scope of use in PDT-assisted skin cancer treatment. In this review, nanocarrier-aided PDT in skin cancer therapies has been discussed with clinical trials and patents. Additionally, novel nanocarriers that are being investigated in PDT are also covered with their future prospects in skin carcinoma treatment.
Collapse
Affiliation(s)
- Shambo Mohanty
- Industrial Research Laboratory, Department of Pharmacy, FD-III, Birla Institute of Technology and Science, Pilani (BITS-PILANI) Pilani Campus, Vidya Vihar Pilani Rajasthan 333031 India
| | - Vaibhavi Meghraj Desai
- Industrial Research Laboratory, Department of Pharmacy, FD-III, Birla Institute of Technology and Science, Pilani (BITS-PILANI) Pilani Campus, Vidya Vihar Pilani Rajasthan 333031 India
| | - Rupesh Jain
- Industrial Research Laboratory, Department of Pharmacy, FD-III, Birla Institute of Technology and Science, Pilani (BITS-PILANI) Pilani Campus, Vidya Vihar Pilani Rajasthan 333031 India
| | - Mukta Agrawal
- School of Pharmacy & Technology Management, NMIMS Hyderabad India
| | | | - Gautam Singhvi
- Industrial Research Laboratory, Department of Pharmacy, FD-III, Birla Institute of Technology and Science, Pilani (BITS-PILANI) Pilani Campus, Vidya Vihar Pilani Rajasthan 333031 India
| |
Collapse
|
2
|
Xie X, Sun T, Pan H, Ji D, Xu Z, Gao G, Miao J, Wang L, Zhang Y, Liu J, Ling Y, Su X. Development of Novel β-Carboline/Furylmalononitrile Hybrids as Type I/II Photosensitizers with Chemo-Photodynamic Therapy and Minimal Toxicity. Mol Pharm 2024; 21:3553-3565. [PMID: 38816926 DOI: 10.1021/acs.molpharmaceut.4c00238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2024]
Abstract
Chemo-photodynamic therapy is a treatment method that combines chemotherapy and photodynamic therapy and has demonstrated significant potential in cancer treatment. However, the development of chemo-photodynamic therapeutic agents with fewer side effects still poses a challenge. Herein, we designed and synthesized a novel series of β-carboline/furylmalononitrile hybrids 10a-i and evaluated their chemo-photodynamic therapeutic effects. Most of the compounds were photodynamically active and exhibited cytotoxic effects in four cancer cells. In particular, 10f possessed type-I/II photodynamic characteristics, and its 1O2 quantum yield increased by 3-fold from pH 7.4 to 4.5. Most interestingly, 10f exhibited robust antiproliferative effects by tumor-selective cytotoxicities and hypoxic-overcoming phototoxicities. In addition, 10f generated intracellular ROS and induced hepatocellular apoptosis, mitochondrial damage, and autophagy. Finally, 10f demonstrated extremely low acute toxicity (LD50 = 1415 mg/kg) and a high tumor-inhibitory rate of 80.5% through chemo-photodynamic dual therapy. Our findings may provide a promising framework for the design of new photosensitizers for chemo-photodynamic therapy.
Collapse
Affiliation(s)
- Xudong Xie
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Tiantian Sun
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Heyu Pan
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Dongliang Ji
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Zhongyuan Xu
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Ge Gao
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Jiefei Miao
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- Department of Oncology, Affiliated Hospital of Nantong University, Nantong 226001, China
| | - Lei Wang
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Yanan Zhang
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Ji Liu
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Yong Ling
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| | - Xing Su
- Department of Pharmacy, Department of Neurosurgery, Affiliated Hospital of Nantong University, Nantong 226001, China
- School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong Key Laboratory of Small Molecular Drug Innovation, Nantong University, Nantong 226001, China
| |
Collapse
|
3
|
Hao Y, Liu T, Zhou H, Xu R, Li K, Chen M, Chen Y. Oxygen-supplying ROS-responsive prodrug for synergistic chemotherapy and photodynamic therapy of colon cancer. Front Pharmacol 2024; 15:1325544. [PMID: 38420201 PMCID: PMC10900137 DOI: 10.3389/fphar.2024.1325544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2023] [Accepted: 01/25/2024] [Indexed: 03/02/2024] Open
Abstract
Introduction: The synergistic treatment of chemotherapy and photodynamic therapy (PDT) has remarkable potential in cancer therapy. However, challenges remain, such as unstable chemotherapeutic drug release, suboptimal targeting, and reduced efficacy of PDT under hypoxic conditions commonly found in solid tumors. Methods: To address these issues, we use camptothecin (CPT) and pheophorbide a (Pa) incorporated through the functional thioketal, which serves as the reactive oxygen species (ROS)-responsive trigger, to construct a ROS-responsive prodrug (CPT-TK-Pa). Subsequently, we co-loaded it with a platinum nanozyme (PtNP) in distearylphosphatidylethanolamine-polyethylene glycol (DSPE-PEG) to obtain the ROS-responsive prodrug nanoparticle (CPT-TK-Pa/Pt NP). Results and Discussion: Specifically, the incorporated PtNP within CPT-TK-Pa/Pt NP positively catalyzes the conversion of hydrogen peroxide (H2O2) to oxygen, thereby ameliorating the hypoxic state of the tumor. This enhanced oxygen generation could replenish the oxygen that is consumed by Pa during 660 nm exposure, enabling controlled CPT release and amplifying the photodynamic response. In vitro investigations reveal the potency of CPT-TK-Pa/Pt NPs in inhibiting colon tumor cells. Given its ROS-responsive release mechanism and enhanced PDT efficacy, CPT-TK-Pa/Pt NP has the potential to be a promising candidate for cancer therapy.
Collapse
Affiliation(s)
- Ying Hao
- Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, Chengdu, China
- West China Hospital, West China School of Nursing, Sichuan University, Chengdu, China
| | - Tailuo Liu
- Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, Chengdu, China
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
| | - Hao Zhou
- Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, Chengdu, China
| | - Runhao Xu
- Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, Chengdu, China
| | - Ka Li
- West China Hospital, West China School of Nursing, Sichuan University, Chengdu, China
| | - Mao Chen
- Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, Chengdu, China
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China
| | - Yuwen Chen
- West China Hospital, West China School of Nursing, Sichuan University, Chengdu, China
| |
Collapse
|
4
|
Klajnert-Maculewicz B, Janaszewska A, Majecka A. Dendrimersomes: Biomedical applications. Chem Commun (Camb) 2023; 59:14611-14625. [PMID: 37999927 DOI: 10.1039/d3cc03182a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2023]
Abstract
In recent years, dendrimer-based vesicles, known as dendrimersomes, have garnered significant attention as highly promising alternatives to lipid vesicles in a variety of biomedical applications. Dendrimersomes offer several advantages, including relatively straightforward synthesis, non-immunogenic properties, stability in circulation, and minimal size variability. These vesicles are composed of Janus dendrimers, which are polymers characterized by two dendritic wedges with different terminal groups - hydrophilic and hydrophobic. This dendrimer structure enables the self-assembly of dendrimersomes. The purpose of this highlight is to provide an overview of recent advancements achieved through the utilization of biomimetic dendrimersomes in various biomedical applications such as drug and nucleic acid delivery.
Collapse
Affiliation(s)
- Barbara Klajnert-Maculewicz
- University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, Pomorska 141/143, 90-236 Lodz, Poland.
| | - Anna Janaszewska
- University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, Pomorska 141/143, 90-236 Lodz, Poland.
| | - Agata Majecka
- University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, Pomorska 141/143, 90-236 Lodz, Poland.
| |
Collapse
|
5
|
Pricl S. The Spicy Science of Dendrimers in the Realm of Cancer Nanomedicine: A Report from the COST Action CA17140 Nano2Clinic. Pharmaceutics 2023; 15:2013. [PMID: 37514199 PMCID: PMC10384593 DOI: 10.3390/pharmaceutics15072013] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 07/12/2023] [Accepted: 07/13/2023] [Indexed: 07/30/2023] Open
Abstract
COST Action CA17140 Cancer Nanomedicine-from the bench to the bedside (Nano2Clinic,) is the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, preclinical testing of efficacy, pharmacokinetics and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies. By promoting scientific exchanges, technological implementation, and innovative solutions, the action aims at providing a timely instrument to rationalize and focus research efforts at the European level in dealing with the grand challenge of nanomedicine translation in cancer, one of the major and societal-burdening human pathologies. Within CA17140, dendrimers in all their forms (from covalent to self-assembling dendrons) play a vital role as powerful nanotheranostic agents in oncology; therefore, the purpose of this review work is to gather and summarize the major results in the field stemming from collaborative efforts in the framework of the European Nano2Clinic COST Action.
Collapse
Affiliation(s)
- Sabrina Pricl
- Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), Department of Engineering and Architecture (DEA), University of Trieste, Piazzale Europa 1, 34127 Trieste, Italy
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, ul. Pomorska 141/143, 90-236 Lodz, Poland
| |
Collapse
|
6
|
Sztandera K, Gorzkiewicz M, Zizzi EA, Dybczak N, Poltorak L, Deriu MA, Klajnert-Maculewicz B. Cellular uptake of rose bengal is mediated by OATP1B1/1B3 transporters. Bioelectrochemistry 2023; 152:108449. [PMID: 37130506 DOI: 10.1016/j.bioelechem.2023.108449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Revised: 03/22/2023] [Accepted: 04/17/2023] [Indexed: 05/04/2023]
Abstract
Due to its fluorescent properties and high yield of singlet oxygen, rose bengal (RB) is one of the most promising photosensitizers for cancer treatment. However, the negative charge of RB molecule may significantly hamper its intracellular delivery by passive diffusion through the cell membrane. Thus, specific membrane protein transporters may be needed. The organic anion transporting polypeptides (OATPs) are a well-characterized group of membrane protein transporters, responsible for cellular uptake of a number of drugs. To our knowledge, this is the first study that evaluates cellular transport of RB mediated by the OATP transporter family. First, electrified liquid-liquid interface, together with biophysical analysis and molecular dynamics simulations were used to characterize the interaction of RB with several models of a cellular membranes. These experiments proved that RB interacts only with the membrane's surface, without spontaneously crossing the lipid bilayer. Evaluation of intracellular uptake of RB by flow cytometry and confocal microscopy showed significant differences in uptake between liver and intestinal cell line models differing in expression of OATP transporters. The use of specific pharmacological inhibitors of OATPs, together with Western blotting and in silico analysis, indicated that OATPs are crucial for cellular uptake of RB.
Collapse
Affiliation(s)
- K Sztandera
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland
| | - M Gorzkiewicz
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland; Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany.
| | - E A Zizzi
- PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Turin, Italy
| | - N Dybczak
- Department of Inorganic and Analytical Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, 91-403 Lodz, Poland
| | - L Poltorak
- Department of Inorganic and Analytical Chemistry, Faculty of Chemistry, University of Lodz, Tamka 12, 91-403 Lodz, Poland
| | - M A Deriu
- PolitoBIOMedLab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Turin, Italy
| | - B Klajnert-Maculewicz
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland
| |
Collapse
|
7
|
Kisakova LA, Apartsin EK, Nizolenko LF, Karpenko LI. Dendrimer-Mediated Delivery of DNA and RNA Vaccines. Pharmaceutics 2023; 15:pharmaceutics15041106. [PMID: 37111593 PMCID: PMC10145063 DOI: 10.3390/pharmaceutics15041106] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/27/2023] [Accepted: 03/28/2023] [Indexed: 04/03/2023] Open
Abstract
DNA and RNA vaccines (nucleic acid-based vaccines) are a promising platform for vaccine development. The first mRNA vaccines (Moderna and Pfizer/BioNTech) were approved in 2020, and a DNA vaccine (Zydus Cadila, India), in 2021. They display unique benefits in the current COVID-19 pandemic. Nucleic acid-based vaccines have a number of advantages, such as safety, efficacy, and low cost. They are potentially faster to develop, cheaper to produce, and easier to store and transport. A crucial step in the technology of DNA or RNA vaccines is choosing an efficient delivery method. Nucleic acid delivery using liposomes is the most popular approach today, but this method has certain disadvantages. Therefore, studies are actively underway to develop various alternative delivery methods, among which synthetic cationic polymers such as dendrimers are very attractive. Dendrimers are three-dimensional nanostructures with a high degree of molecular homogeneity, adjustable size, multivalence, high surface functionality, and high aqueous solubility. The biosafety of some dendrimers has been evaluated in several clinical trials presented in this review. Due to these important and attractive properties, dendrimers are already being used to deliver a number of drugs and are being explored as promising carriers for nucleic acid-based vaccines. This review summarizes the literature data on the development of dendrimer-based delivery systems for DNA and mRNA vaccines.
Collapse
Affiliation(s)
- Lyubov A. Kisakova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Kol’tsovo, Russia
| | - Evgeny K. Apartsin
- CBMN, UMR 5248, CNRS, Bordeaux INP, University Bordeaux, F-33600 Pessac, France
| | - Lily F. Nizolenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Kol’tsovo, Russia
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Kol’tsovo, Russia
| |
Collapse
|
8
|
de la Mata FJ, Gómez R, Cano J, Sánchez‐Nieves J, Ortega P, Gallego SG. Carbosilane dendritic nanostructures, highly versatile platforms for pharmaceutical applications. WIRES NANOMEDICINE AND NANOBIOTECHNOLOGY 2022; 15:e1871. [PMID: 36417901 DOI: 10.1002/wnan.1871] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2022] [Revised: 10/21/2022] [Accepted: 10/23/2022] [Indexed: 11/25/2022]
Abstract
Dendrimers are multifunctional molecules with well-defined size and structure due to the step-by-step synthetic procedures required in their preparation. Dendritic constructs based on carbosilane scaffolds present carbon-carbon and carbon-silicon bonds, which results in stable, lipophilic, inert, and flexible structures. These properties are highly appreciated in different areas, including the pharmaceutical field, as they can increase the interaction with cell membranes and improve the therapeutic action. This article summarizes the most recent advances in the pharmaceutical applications of carbosilane dendritic molecules, from therapeutics to diagnostics and prevention tools. Dendrimers decorated with cationic, anionic, or other moieties, including metallodendrimers; supramolecular assemblies; dendronized nanoparticles and surfaces; as well as dendritic networks like hydrogels are described. The collected examples confirm the potential of carbosilane dendrimers and dendritic materials as antiviral or antibacterial agents; in therapy against cancer, neurodegenerative disease, or oxidative stress; or many other biomedical applications. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Collapse
Affiliation(s)
- Francisco Javier de la Mata
- Department of Organic and Inorganic Chemistry, Faculty of Sciences, and Research Institute in Chemistry “Andrés M. del Río” (IQAR) Universidad de Alcala Alcalá de Henares Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III
- Institute Ramón y Cajal for Health Research (IRYCIS) Madrid Spain
| | - Rafael Gómez
- Department of Organic and Inorganic Chemistry, Faculty of Sciences, and Research Institute in Chemistry “Andrés M. del Río” (IQAR) Universidad de Alcala Alcalá de Henares Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III
- Institute Ramón y Cajal for Health Research (IRYCIS) Madrid Spain
| | - Jesús Cano
- Department of Organic and Inorganic Chemistry, Faculty of Sciences, and Research Institute in Chemistry “Andrés M. del Río” (IQAR) Universidad de Alcala Alcalá de Henares Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III
- Institute Ramón y Cajal for Health Research (IRYCIS) Madrid Spain
| | - Javier Sánchez‐Nieves
- Department of Organic and Inorganic Chemistry, Faculty of Sciences, and Research Institute in Chemistry “Andrés M. del Río” (IQAR) Universidad de Alcala Alcalá de Henares Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III
- Institute Ramón y Cajal for Health Research (IRYCIS) Madrid Spain
| | - Paula Ortega
- Department of Organic and Inorganic Chemistry, Faculty of Sciences, and Research Institute in Chemistry “Andrés M. del Río” (IQAR) Universidad de Alcala Alcalá de Henares Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III
- Institute Ramón y Cajal for Health Research (IRYCIS) Madrid Spain
| | - Sandra García Gallego
- Department of Organic and Inorganic Chemistry, Faculty of Sciences, and Research Institute in Chemistry “Andrés M. del Río” (IQAR) Universidad de Alcala Alcalá de Henares Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III
- Institute Ramón y Cajal for Health Research (IRYCIS) Madrid Spain
| |
Collapse
|
9
|
Sztandera K, Gorzkiewicz M, Wang X, Boye S, Appelhans D, Klajnert-Maculewicz B. pH-stable polymersome as nanocarrier for post-loaded rose bengal in photodynamic therapy. Colloids Surf B Biointerfaces 2022; 217:112662. [PMID: 35785717 DOI: 10.1016/j.colsurfb.2022.112662] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2022] [Revised: 06/23/2022] [Accepted: 06/24/2022] [Indexed: 10/17/2022]
Abstract
Photodynamic therapy is one of the best alternatives to chemo-, radio- or surgical therapy, as it is noninvasive and causes no severe side effects. The mechanism of photodynamic therapy involves activation of the drug (photosensitizer) with light of appropriate wavelength, which combined with molecular oxygen, leads to production of reactive oxygen species. This starts a cascade of reactions leading to cell death. Thus, the efficiency of this therapy is based mainly on the properties of a photosensitizer, including singlet oxygen yield and accumulation in the tumor area. Current research is aimed at applying nanosystems for the improvement of availability and photodynamic properties of photosensitizers. In order to improve the activity and increase photodynamic potential of rose bengal, one of the most promising drugs in anticancer photodynamic therapy, several drug delivery systems were developed. Among them, polymersomes represent a group of innovative polymeric vesicles mimicking membranous cell structures. Polymersomes are nanosystems made of amphiphilic block copolymers, possessing a spherical, liposome-like architecture. Within this study we present biophysical and in vitro biological characterization of this novel pH-stable nanosystem, which due to the improvement of singlet oxygen and reactive oxygen species (ROS) production by rose bengal is a good candidate for nanocarrier in photodynamic therapy.
Collapse
Affiliation(s)
- K Sztandera
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland.
| | - M Gorzkiewicz
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland; Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Germany
| | - X Wang
- Dongguan Hospital, Southern Medical University, Dongguan 523059, PR China
| | - S Boye
- Leibniz Institute for Polymer Research Dresden, 6 Hohe St., 01069 Dresden, Germany
| | - D Appelhans
- Leibniz Institute for Polymer Research Dresden, 6 Hohe St., 01069 Dresden, Germany
| | - B Klajnert-Maculewicz
- Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska St., 90-236 Lodz, Poland
| |
Collapse
|